JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2016, 65(3):99-103 | DOI: 10.36290/csf.2016.020

Ageing and Alzheimer disease - system dynamics model prediction

Hana Tomášková1,*, Jitka Kühnová2, Kamil Kuča3
1 Fakulta informatiky a managementu, Univerzita Hradec Králové
2 Přírodovědecká fakulta, Univerzita Hradec Králové
3 Centrum základního a aplikovaného výzkumu (CZAV), Univerzita Hradec Králové

The aim of the paper is to describe asystem dynamics model applied on aprediction of the number of patients with Alzheimer's disease in the EU in the future and related financial impacts. Dementia resulting from Alzheimer's disease is the most widely spread type of dementia and is highly connected with the age of the person - the patient. Most people are diagnosed with Alzheimer's disease when they are older than 64. The ageing of population will be an ongoing problem in the next few decades due to alow birth rate and increasing life expectancy. This is areason to focus on prediction models of Alzheimer's disease and its impact on economy. The paper presents adynamic modelling approach of system dynamics. The created model of the EU population and patients with AD is expanded by afinancial submodel at the end. This submodel estimates the cost on patients from three available cost studies.

Keywords: system dynamic; Alzhimer's disease; population ageing
Grants and funding:

Článek vznikl za podpory projektů GAČR #14-02424S a Specifického studentského projektu "Ekonomické a manažerské aspekty biomedicínských procesů".

Received: May 4, 2016; Accepted: June 16, 2016; Published: March 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tomášková H, Kühnová J, Kuča K. Ageing and Alzheimer disease - system dynamics model prediction. Čes. slov. farm. 2016;65(3):99-103. doi: 10.36290/csf.2016.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hampel H., Prvulovic D., Teipel S., Jessen F., Luckhaus C., Frölich L., Riepe M. W., Dodel R., Leyhe T., Bertram L., Hoffmann W., Faltraco F. The future of Alzheimer's disease: The next 10 years. Prog. Neurobiol. 2011; 95(4), 718-728. Go to original source... Go to PubMed...
    2. Barker W. W., Luis C. A., Kashuba A., Luis M., Harwood D. G., Loewenstein D., Waters C., Jimison P., Shepherd E., Sevush S., Graff-Radford N., Newland D., Todd M., Miller B., Gold M., Heilman K., Doty L., Goodman I., Robinson B., Pearl G., Dickson D., Duara R. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis. Assoc. Disord. 2002; 16(4), 203-212. Go to original source... Go to PubMed...
    3. Wilson R. S., Segawa E., Boyle P. A., Anagnos S. E., Hizel L. P., Bennett D. A. The natural history of cognitive decline in Alzheimer's disease. Psychol. Aging 2012; 27(4), 1008-1017. Go to original source... Go to PubMed...
    4. alz.org. What Is Alzheimer's? Retrieved from The Alzheimer's Association. http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp (20. 1. 2016)
    5. Alzheimer Association 2015. Alzheimer's disease facts and figures. Alzheimers Dement 2015; 11(3), 332-384. doi:http://dx.doi.org/10.1016/j.jalz.2015.02.003 Go to original source... Go to PubMed...
    6. Maresova P., Mohelska H., Dolejs J., Kuca K. Socio-economic Aspects of Alzheimer's Disease. Curr Alzheimer Res 2015; 12(9), 903-911. Go to original source... Go to PubMed...
    7. Mohelska H., Maresova P., Valis M., Kuca K. Alzheimer's disease and its treatment costs: case study in the Czech Republic. Neuropsychiatr. Dis. Treat. 2015; 11, 2349-2354. Go to original source... Go to PubMed...
    8. Wimo A., Jönsson L., Gustavsson A., McDaid D., Ersek K., Georges J., Gulacsi L., Karpati K., Kenigsberg P., Valtonen H. The economic impact of dementia in Europe in 2008 - cost estimates from the Eurocode project. Int. J. Geriatr. Psychiatry 2011; 26(8), 825-832. Go to original source... Go to PubMed...
    9. Mohelska H., Maresova P. Economic and Managerial Aspects of Alzheimer's Disease in The Czech Republic, Procedia Economics and Finance 2015; 23, 521-524. http://dx.doi.org/10.1016/S2212-5671(15)00343-3. Go to original source...
    10. Maresova P., Klimova B., Kuca K. Alzheimer's disease: Cost cuts call for novel drugs development and national stratégy. Čes. Slov. Farm. 2015; 64, 25-30. Go to original source...
    11. Maresova P., Tomaskova H., Kuca K. The use of simulation modelling in the analysis of the economic aspects of diseases in old age. In: Conference: EBES Eurasian Business and Economics Society, Barcelona, 2014; 369-377. Go to original source...
    12. Carrillo M. Leveraging global resources to end the Alzheimer's pandemic. Alzheimers Dement 2013; 9(4), 363-365. doi:10.1016/j.jalz.2013.05.1768 Go to original source... Go to PubMed...
    13. Handels R. L., Wolfs C. A., Aalten P., Joore M. A., Verhey F. R., Severens J. L. Diagnosing Alzheimer's disease: a systematic review of economic evaluations. Alzheimers Dement 2014; 10(2), 225-237. doi:http://dx.doi.org/10.1016/j.jalz.2013.02.005. URL Go to original source... Go to PubMed...
    14. Klimova B., Maresova P., Valis M., Hort J., Kuca K. Alzheimer's disease and language impairments: social intervention and medical treatment. Clin. Interv. Aging 2015; 10, 1401-1408. doi:10.2147/cia.s89714. URL http://europepmc.org/articles/PMC4555976 Go to original source... Go to PubMed...
    15. Maresova P., Klimova B. Supporting technologies for old people with dementia: a review. IFAC-PapersOnLine 2015; 48(4), 129-134. doi:http://dx.doi.org/10.1016/j.ifacol.2015.07.020. Go to original source...
    16. Maresova P., Mohelska H., Kuca K. Economics aspects of ageing population. Procedia Economics and Finance 2015; 23, 534-538. doi:http://dx.doi.org/10.1016/S2212-5671(15)00492-X. Go to original source...
    17. Mohelska H., Maresova P., Kuca K. Economic and managerial aspects of Alzheimer's disease in the czech republic. Procedia Soc. Behav. Sci. 2014; 23, 521-524. Go to original source...
    18. Tako A., Robinson S. The application of discrete event simulation and system dynamics in the logistics and supply chain context. Decis. Support Syst. 2012; 802-815. Go to original source...
    19. Sterman, J. Business dynamics: Systems thinking and modeling for a complex world. New York, NY: Irwin McGraw-Hill 2000.
    20. Forrester J. Industrial Dynamics. Cambridge, MA: MIT Press 1961.
    21. Segovia-Juarez J. L., Ganguli S., Kirschner D. Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model, J. Theor. Biol. 2004; 231(3), 357-376. http://dx.doi.org/10.1016/j.jtbi.2004.06.031 Go to original source... Go to PubMed...
    22. Nefti S., Manzoor U., Manzoor S. Cognitive agent based intelligent warning system to monitor patients suffering from dementia using ambient assisted living. Information Society (i-Society) 2010; 92-97. Go to original source...
    23. Boger J., Hoey J., Poupart P., Boutilier C., Fernie G., Mihailidis A. A planning system based on Markov decision processes to guide people with dementia through activities of daily living, in IEEE Transactions on Information Technology in Biomedicine, vol. 10, no. 2, pp. 323-333, April 2006. doi:10.1109/TITB.2006.864480 Go to original source... Go to PubMed...
    24. Tomaskova H., Kuhnova J., Kuca, K. Economic model of Alzheimer's disease. In: Proceedings of the 25th International Business Information Management Association Conference - Innovation Vision 2020: From Regional Development Sustainability to Global Economic Growth, IBIMA 2015; 3120-3127.
    25. EUROSTAT, http://ec.europa.eu/eurostat (9. 11. 2015).
    26. Arizaga R. Epidemiology of dementia. Dementia: a multidisciplinary approach 2005; 7-17.
    27. Brookmeyer R., Corrada M. M., Curriero F. C., Kawas A. C. Survival follwing and diagnosis of Alzheimer disease. Arch. Neurol. 2002; 59(11): 1764-1767. doi:10.1001/archneur.59.11.1764. Go to original source... Go to PubMed...
    28. Tomaskova H., Kuhnova J., Cimler R., Dolezal O., Kuca K. Prediction of population with Alzheimer's disease in EU using system dynamics model. Neuropsychiatr. Dis. Treat. 2016; (in press).
    29. Gerves C., Chauvin P., Bellanger M. Evaluation of full costs of care for patients with Alzheimer's disease in france: The predominant role of informal care. J. Public. Health Policy 2014; 116(1), 114-122. Go to original source... Go to PubMed...
    30. Schwarzkopf L. M., Marx P., Mehlig H., Wunder S., Leidl R., Donath C., Graessel E. Costs of care for dementia patients in community setting: An analysis for mild and moderate disease stage. Value Health 2011; 14(6), 827-835. Go to original source... Go to PubMed...
    31. Jones R., Romeo R., Trigg R. K., Sato A., King D., Niecko T., Lacey L. Dependence in Alzheimer's disease and service use costs, quality of life, and caregiver burden: The {DADE} study. Alzheimers Dement 2015; 11(3), 280-290. Go to original source... Go to PubMed...
    32. Dodel R., Belger M., Reed C., Wimo A., Jones R., Happich M., Haro J. Determinants of societal costs in Alzheimer's disease: Geras study baseline results. Alzheimers Dement 2015; 11(8), 933-945. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.